AnaptysBio, Inc. (ANAB)
54.36
+0.18
(+0.32%)
USD |
NASDAQ |
Feb 23, 16:00
54.36
0.00 (0.00%)
After-Hours: 19:59
AnaptysBio Research and Development Expense (Quarterly) : 31.27M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vanda Pharmaceuticals, Inc. | 29.01M |
| Nektar Therapeutics | 27.25M |
| Rigel Pharmaceuticals, Inc. | 7.353M |
| CorMedix, Inc. | 5.098M |
| Verastem, Inc. | 28.99M |